The Cellular Immunology and Metabolism Core (CIMC) of the LSU Cancer Center provides cutting edge flow cytometry, immunology and metabolism technologies LSUHSC investigators including COBRE PJI's, and to other users in our region. The CIMC laboratory now provides comprehensive analytic flow cytometry, high- speed cell sorting services, functional assays including antigen-specific and mitogen-induced cell proliferation, cytokine production, cell death and survival, cell mediated cytotoxicity, and effector T cell frequency. The CIMC also acquired and developed the infrastructure and expertise to study cellular metabolism, including oxygen consumption and acidification rates, mitochondrial function; and the detection of immune mediators through multiplex approaches. Therefore, state-of-the-art services of the CIMC are very well suited to support the needs of PJIs of the new Phase I COBRE application ?Center for translational Viral Oncology? (CTVO). This will be done by fully utilizing present services and resources, and by expending their expertise to identify new biomarkers for virus-induced cancer, evaluation of cell growth and cell death responses associated with the expression of viral oncoproteins and anticancer treatment. In addition, innovative approaches, which are continuously implemented by the CIMC personnel will allow PJIs and their mentors to develop new experimental strategies explaining virus-induced changes at the levels of tumor cell signaling, epigenetic regulation and tumor cell energy metabolism, thereby increasing their chances for high impact publications and federal and foundation-related funding. These advanced technologies have positioned the CIMC as the leading laboratory in cancer and immunology in the region, which has resulted in an increased number of users, including PJIs of the CTVO, and its integration as a core laboratory at the LSUHSC School of Medicine and the LSU-Cancer Center. ! !

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM121288-02
Application #
9545023
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Louisiana State Univ Hsc New Orleans
Department
Type
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Ungerleider, Nathan; Concha, Monica; Lin, Zhen et al. (2018) The Epstein Barr virus circRNAome. PLoS Pathog 14:e1007206
Dai, Lu; Zhao, Mengmeng; Jiang, Wei et al. (2018) KSHV co-infection, a new co-factor for HPV-related cervical carcinogenesis? Am J Cancer Res 8:2176-2184
Mills, Kylie L; Gomes, Angelica M; Standlee, Courtney R et al. (2018) Gas6 is dispensable for pubertal mammary gland development. PLoS One 13:e0208550
Lassak, Adam; Dean, Mathew; Wyczechowska, Dorota et al. (2018) Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival. Mol Cell Biol 38:
Qiao, Jing; Cao, Yueyu; Zabaleta, Jovanny et al. (2018) Regulation of Virus-Associated Lymphoma Growth and Gene Expression by Bacterial Quorum-Sensing Molecules. J Virol 92:
Dai, Lu; Del Valle, Luis; Miley, Wendell et al. (2018) Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development. Oncogene 37:4534-4545
Dai, Lu; Smith, Charles D; Foroozesh, Maryam et al. (2018) The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer 142:2153-2162
Dai, Lu; Qiao, Jing; Del Valle, Luis et al. (2018) KSHV co-infection regulates HPV16+ cervical cancer cells pathogenesis in vitro and in vivo. Am J Cancer Res 8:708-714
Lin, Zhen; Nguyen, Christian; Xu, Beibei et al. (2018) Interleukin-17A in the Pathogenesis of Lung Adenocarcinoma. Ann Am Thorac Soc 15:S125
Dai, Lu; Lin, Zhen; Jiang, Wei et al. (2017) Lipids, lipid metabolism and Kaposi's sarcoma-associated herpesvirus pathogenesis. Virol Sin 32:369-375

Showing the most recent 10 out of 13 publications